AZ chief 'smart choice' for reform talks

AstraZeneca CEO David Brennan came up through sales, and that's why he was a smart choice to lead talks on Obama's healthcare reforms, the Times of London says. Report

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.